OQS
MLTX icon

Occudo Quantitative Strategies’s MoonLake Immunotherapeutics MLTX Stock Holding History

Occudo Quantitative Strategies’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,918
Closed -$394K – 1045
2023
Q3 		$394K Buy
+6,918
New +$382K 0.05% 575

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Occudo Quantitative Strategies's MLTX Position: Q4 2023 in Review

Occudo Quantitative Strategies sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2023, closing a stake of 6,918 shares — an estimated $394K sold.

Occudo Quantitative Strategies first reported a position in MLTX in Q3 2023 and held it in 1 quarter. The position peaked at $394K in Q3 2023. 125 funds tracked by Wall St. Rank hold MLTX as of Q4 2023.

  • Occudo Quantitative Strategies reported no remaining MoonLake Immunotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 6,918 MoonLake Immunotherapeutics shares in Q4 2023, an estimated $394K.
  • Occudo Quantitative Strategies first reported a position in MoonLake Immunotherapeutics in Q3 2023 and held it in 1 quarter.
  • Occudo Quantitative Strategies's MoonLake Immunotherapeutics position peaked at $394K in Q3 2023.
  • 125 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2023, filed 14 Feb 2024.